Quantcast
Last updated on April 23, 2014 at 10:40 EDT

Latest autoimmune disease Stories

2014-03-06 12:27:02

ORLANDO, Fla., March 6, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK). TNI BioTech has spent the last year developing a manufacturing and distribution network for sale of LDN into emerging nations and has had discussions with the FDA and EMA to begin clinical trials in the United States. The Company has considered whether to...

2014-02-11 16:25:01

ORLANDO, Fla., Feb. 11, 2014 /PRNewswire/ -- TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development of?innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC") that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing...

2014-01-22 23:21:15

The Paleo Approach: Reverse Autoimmune Disease and Heal Your Body shows the scientific evidence that proves the correlation between autoimmune disorders and diet/lifestyle. Altanta, GA (PRWEB) January 22, 2014 Sarah Ballantyne, PhD, respected health blogger, autoimmune expert and dedicated mom delivers the first-ever complete guidebook to help manage autoimmune disease through Paleo diet and lifestyle in: The Paleo Approach: Reverse Autoimmune Disease and Heal Your Body. In this...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2014-01-13 12:27:53

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQ(TM), to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The...

2014-01-07 23:01:17

A 2.5-Day Summit Providing Groundbreaking Approaches to Treating Patients With Interrelated Autoimmune Conditions Malvern, PA (PRWEB) January 07, 2014 The Interdisciplinary Autoimmune Summit (IAS) is pleased to announce the Keynote Address to be presented by Noel R. Rose, MD, PhD, Professor of Pathology, Professor of Molecular Microbiology and Immunology, Director, Johns Hopkins Center for Autoimmune Disease Research, The Johns Hopkins Medical Institutions. On Friday, June 20, 2014 at...

2013-12-19 08:27:47

DUBLIN, Dec. 19, 2013. /PRNewswire/-- Research and Markets (http://www.researchandmarkets.com/research/785rc2/global_autoimmune) has announced the addition of the "Global Autoimmune Disease Diagnostics Market" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This research service evaluates the global autoimmune disease diagnostics markets from 2009 to 2018. The market includes two segments, which include analysis for the markets for localized autoimmune...

2013-12-18 08:28:17

- Results of Phase 1/2 trial for BL-7010 expected in mid-2014 - JERUSALEM, Dec. 18, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac...

2013-12-11 13:08:56

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute (TSRI) has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans. The study was published recently online ahead of print by the journal Arthritis & Rheumatism. The study showed the compound, known as SR2211, blocked development of virtually all symptoms...

2013-11-12 23:33:00

Groundbreaking annual conference brings together experts from across the autoimmune disease spectrum. Malvern, PA (PRWEB) November 12, 2013 HMP Communications Holdings, LLC, a leader in healthcare communications and education, is proud to announce the launch of the Interdisciplinary Autoimmune Summit (IAS), a revolutionary new initiative that brings together experts and specialists across the autoimmune disease spectrum for two and a half days of learning, networking, and collaborating....